Skip to main content
OpenTrials
Completed

NCT Number: NCT07240298

Comparison of Triglyceride-Glucose Index and Atherogenic Indices Between Patients With Lipedema and Obese Controls

Women aged 18-75 years with a clinical diagnosis of lipedema and an obese control group will be included in the study. Sociodemographic and clinical data (age, height, weight, medications, etc.) of the participants will be recorded. For laboratory evaluation, fasting blood test results obtained within the last three months (including fasting glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides) will be used. Based on these parameters, metabolic and atherogenic risk indicators such as the Triglyceride-Glucose Index (TyG), TyG-BMI, Atherogenic Index of Plasma (AIP), Atherogenic Coefficient (AC), Castelli Risk Index I (CRI-I), and Castelli Risk Index II (CRI-II) will be calculated. No additional biochemical tests will be collected from participants; analyses will be performed using existing laboratory results.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lipedema Connective Tissue Diseases Skin and Connective Tissue Diseases

Age range

18 year–75 year

Sex eligibility

Female

Study type

Observational

Primary location

Istanbul Physical Medicine Rehabilitation Training and Research Hospital

Istanbul, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinically diagnosed with lipedema
  • Obese control group with BMI ≥30 kg/m² who do not meet lipedema criteria
  • Aged between 18 and 75 years
  • Availability of fasting lipid profile and fasting glucose tests within the past 3 months
  • Provided voluntary informed consent

Exclusion criteria

  • Use of medications that routinely affect lipid or glucose metabolism: statins, fibrates, niacin, ezetimibe, high-dose omega-3 supplements, GLP-1 receptor agonists, SGLT2 inhibitors, or systemic corticosteroids (regular use within the past 3 months)
  • Presence of rheumatologic diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus) or active malignancy
  • Neurological disorders (e.g., polyneuropathy, multiple sclerosis, history of stroke)
  • Pregnancy or lactation
  • History of lower extremity surgery or major trauma within the past 6 months
  • Received injection therapy or physical therapy for the lower extremities within the past 6 months
  • Active infection or dermatological disease affecting the lower extremities
  • History of significant venous insufficiency or acute deep vein thrombosis (DVT)
  • Alcohol or substance abuse
  • Smoking

Treatment and study plan

No intervention

Other

No intervention

Primary outcomes

  1. Triglyceride-Glucose Index (TyG):

    Time frame: Baseline

    The TyG index will be calculated as ln [fasting triglycerides (mg/dL) × fasting glucose (mg/dL) / 2]. It serves as a surrogate marker for insulin resistance. Higher values indicate greater metabolic risk.

Secondary outcomes

  1. TyG-BMI

    Time frame: Baseline

    Calculated by multiplying the TyG index by body mass index (BMI). Higher values indicate increased insulin resistance and metabolic risk.

  2. Atherogenic Index of Plasma (AIP):

    Time frame: Baseline

    Calculated as log (triglycerides / HDL-cholesterol). Higher AIP values reflect greater atherogenic risk.

  3. Atherogenic Coefficient (AC):

    Time frame: Baseline

    Calculated as (total cholesterol - HDL-cholesterol) / HDL-cholesterol. Higher scores indicate higher atherogenic potential.

  4. Castelli Risk Index I (CRI-I):

    Time frame: Baseline

    Calculated as total cholesterol / HDL-cholesterol. Higher values indicate increased cardiovascular risk.

  5. Castelli Risk Index II (CRI-II):

    Time frame: Baseline

    Calculated as LDL-cholesterol / HDL-cholesterol. Higher scores represent greater atherogenic risk.

Sponsors and collaborators

Lead sponsor

Istanbul Physical Medicine Rehabilitation Training and Research Hospital

Other Gov

Registry information

Official study title

Comparison of Triglyceride-Glucose Index and Atherogenic Indices Between Patients With Lipedema and Obese Controls: A Cross-Sectional Study

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Nov 20, 2025
Registry last updated
Nov 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.